Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators.

N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.

PMID:
28304224
2.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators.

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

3.

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group.

JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.

PMID:
26325557
4.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators.

N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.

5.

Ivabradine in stable coronary artery disease without clinical heart failure.

Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R; SIGNIFY Investigators.

N Engl J Med. 2014 Sep 18;371(12):1091-9. doi: 10.1056/NEJMoa1406430. Epub 2014 Aug 31.

6.

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators.

N Engl J Med. 2013 Oct 3;369(14):1327-35. doi: 10.1056/NEJMoa1305889. Epub 2013 Sep 2.

7.

Vorapaxar in the secondary prevention of atherothrombotic events.

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators.

N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24.

8.

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.

Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB; RUBY-1 Investigators.

Eur Heart J. 2011 Oct;32(20):2541-54. doi: 10.1093/eurheartj/ehr334. Epub 2011 Aug 30.

9.

Identification of the C2∏-X2Σ+ band system of AlO in the ultraviolet galvanoluminescence obtained during aluminum anodization.

Sarvan M, Perić M, Zeković L, Stojadinović S, Belča I, Petković M, Kasalica B.

Spectrochim Acta A Mol Biomol Spectrosc. 2011 Oct 15;81(1):672-8. doi: 10.1016/j.saa.2011.06.072. Epub 2011 Jul 6.

PMID:
21795103
10.

Apixaban with antiplatelet therapy after acute coronary syndrome.

Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators.

N Engl J Med. 2011 Aug 25;365(8):699-708. doi: 10.1056/NEJMoa1105819. Epub 2011 Jul 24.

11.

Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.

Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjølie AK; DIRECT Study Group.

Diabetologia. 2011 Jun;54(6):1298-303. doi: 10.1007/s00125-010-2040-1. Epub 2011 Jan 12.

PMID:
21225239
12.

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.

Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1385-93. doi: 10.1016/S0140-6736(08)61411-7. Epub 2008 Sep 25.

13.

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.

Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1394-402. doi: 10.1016/S0140-6736(08)61412-9. Epub 2008 Sep 25.

PMID:
18823656
14.

Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.

Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA; Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators.

Lancet. 2008 May 24;371(9626):1761-8. doi: 10.1016/S0140-6736(08)60763-1.

PMID:
18502300
15.

[Specific IgG and IgE antibodies in house dust mite asthmatic patients and control probands].

Sarvan M, Noyan O, Debelić M.

Pneumologie. 1990 Feb;44 Suppl 1:375-7. German.

PMID:
2367421
16.

[Importance of social pediatric factors in infant mortality. Experiences in Yugoslavia].

Sarvan M.

Monatsschr Kinderheilkd. 1971 Feb;119(2):85-7. German. No abstract available.

PMID:
5546764
17.

[Some problems of anti-infective therapy of acute pneumopathies in infancy].

Sarvan M.

Med Glas. 1966 Aug;20(8):269-72. Serbian. No abstract available.

PMID:
5975321
18.

[The influence of nontherapeutic factors on the results of treatment of tuberculous meningitis].

SARVAN M, ZEC N.

Monatsschr Kinderheilkd. 1961 Mar;109:195-7. German. No abstract available.

PMID:
13746626
19.

[The problem of vaccinations in Yugoslavia (their calendar)].

SARVAN M.

Rev Immunol Ther Antimicrob. 1960 Jan-Mar;24:271-7. French. No abstract available.

PMID:
14441850
20.

[Comparative effects of hormone & salicylate therapy of Bouillaud's disease].

SARVAN M, STOJKOV N.

Sem Hop. 1958 Mar 24;34(14/3):868-70P. French. No abstract available.

PMID:
13555987

Supplemental Content

Loading ...
Support Center